About the Program

mRCC Discovery is a video-based educational activity addressing best practices, current challenges and solutions in the management of patients with metastatic renal cell carcinoma (mRCC).

Learning Objectives

By viewing these videos, participants will be able to:

  • Recognize the latest advancements in the management of diverse mRCC patient profiles
  • Apply the most recent clinical data and guidelines in mRCC management to day-to-day practice.

Scientific Development Committee

Dr. Georg Bjarnason, MD, FRCPC
Medical Oncologist, Senior Scientist
Sunnybrook Odette Cancer Centre
Toronto, ON

Daniel Heng, MD, FRCPC
Medical Oncologist
Tom Baker Cancer Centre
Clinical Associate Professor of Medicine
University of Calgary
Calgary, Alberta

Dr. Sébastien Hotte, MD, MSc, FRCPC
Medical Oncologist
Juravinski Cancer Centre
Associate Professor
McMaster University
Hamilton, ON

Anil Kapoor, MD, FRCSC
Chair, Kidney Cancer Research Network of Canada (KCRNC)
Professor of Surgery (Urology)
McMaster University
Head, Genito-Urinary Oncology Program
Juravinski Cancer Centre
Hamilton, Ontario

Christian Kollmannsberger, MD, FRCPC
Medical Oncologist
British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre
Clinical Professor
University of British Columbia
Vancouver, British Columbia

Denis Soulières, MD, MSc, FRCPC
Hematologist/Medical Oncologist
Centre Hospitalier de l’Université de Montréal (CHUM)
Clinical Associate Professor of Medicine
University of Montreal
Montreal, Quebec

1. Dr. Daniel Heng

What are the principles of risk stratification in mRCC?

2. Dr. Christian Kollmannsberger

What are the latest guidelines available in mRCC and how can they be applied in Canada?

3. Dr. Anil Kapoor

What is the optimal sequence of treatment ?

4. Dr. Denis Soulières

Individualizing systemic therapy for mRCC – where do we stand and what is the goal?

5. Dr. Anil Kapoor

How do you adapt mRCC treatment to elderly patients?

6. Dr. Daniel Heng

How do you manage drug-related toxicity in mRCC patients?

7. Dr. Daniel Heng

What kind(s) of psychological support can be offered to mRCC patients in clinics?

8. Dr. Christian Kollmannsberger

What are the key ongoing and upcoming studies and trials in mRCC?

9. Dr. Georg Bjarnason

What are the current recommendations regarding individualization of sunitinib dose in mRCC?

10. Dr. Sébastien Hotte

What are the key highlights from the 2019 Canadian mRCC guideline update?

Click here to complete the Section 3 Questionnaire

About the Program

mRCC Discovery is a video-based educational activity addressing best practices, current challenges and solutions in the management of patients with metastatic renal cell carcinoma (mRCC).

Learning Objectives

By viewing these videos, participants will be able to:

  • Recognize the latest advancements in the management of diverse mRCC patient profiles
  • Apply the most recent clinical data and guidelines in mRCC management to day-to-day practice.

Scientific Development Committee

Dr. Georg Bjarnason, MD, FRCPC
Medical Oncologist, Senior Scientist
Sunnybrook Odette Cancer Centre
Toronto, ON

Daniel Heng, MD, FRCPC
Medical Oncologist
Tom Baker Cancer Centre
Clinical Associate Professor of Medicine
University of Calgary
Calgary, Alberta

Dr. Sébastien Hotte, MD, MSc, FRCPC
Medical Oncologist
Juravinski Cancer Centre
Associate Professor
McMaster University
Hamilton, ON

Anil Kapoor, MD, FRCSC
Chair, Kidney Cancer Research Network of Canada (KCRNC)
Professor of Surgery (Urology)
McMaster University
Head, Genito-Urinary Oncology Program
Juravinski Cancer Centre
Hamilton, Ontario

Christian Kollmannsberger, MD, FRCPC
Medical Oncologist
British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre
Clinical Professor
University of British Columbia
Vancouver, British Columbia

Denis Soulières, MD, MSc, FRCPC
Hematologist/Medical Oncologist
Centre Hospitalier de l’Université de Montréal (CHUM)
Clinical Associate Professor of Medicine
University of Montreal
Montreal, Quebec

1. Dr. Daniel Heng

What are the principles of risk stratification in mRCC?

2. Dr. Christian Kollmannsberger

What are the latest guidelines available in mRCC and how can they be applied in Canada?

3. Dr. Anil Kapoor

What is the optimal sequence of treatment ?

4. Dr. Denis Soulières

Individualizing systemic therapy for mRCC – where do we stand and what is the goal?

5. Dr. Anil Kapoor

How do you adapt mRCC treatment to elderly patients?

6. Dr. Daniel Heng

How do you manage drug-related toxicity in mRCC patients?

7. Dr. Daniel Heng

What kind(s) of psychological support can be offered to mRCC patients in clinics?

8. Dr. Christian Kollmannsberger

What are the key ongoing and upcoming studies and trials in mRCC?

9. Dr. Georg Bjarnason

What are the current recommendations regarding individualization of sunitinib dose in mRCC?

10. Dr. Sébastien Hotte

What are the key highlights from the 2019 Canadian mRCC guideline update?

Click here to complete the Section 3 Questionnaire
This initiative was made possible through an Educational Grant by Pfizer Canada Inc. and has received in-kind support from Pfizer Canada Inc. in the form of logistical support.
This initiative was made possible through an Educational Grant by Pfizer Canada Inc. and has received in-kind support from Pfizer Canada Inc. in the form of logistical support.